Summary of Study ST001751
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001114. The data can be accessed directly via it's Project DOI: 10.21228/M8Q39V This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST001751 |
Study Title | Free fatty acid analysis of NIH-3T3 cells treated with apoptotic inducers |
Study Type | Targeted lipidomics |
Study Summary | Changes of free fatty acid profiles in mouse NIH-3T3 fibroblasts treated with mechanistically diverse apoptotic inducers for 48h. |
Institute | University of Innsbruck |
Department | Michael Popp Institute |
Last Name | Koeberle |
First Name | Andreas |
Address | Mitterweg 24, Innsbruck, Tyrol, 6020, Austria |
andreas.koeberle@uibk.ac.at | |
Phone | +43 512 507 57903 |
Submit Date | 2021-04-02 |
Raw Data Available | Yes |
Raw Data File Type(s) | wiff |
Analysis Type Detail | LC-MS |
Release Date | 2021-05-01 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Factors:
Subject type: Cultured cells; Subject species: Mus musculus (Factor headings shown in green)
mb_sample_id | local_sample_id | hours |
---|---|---|
SA163885 | VJ_17.05.17-n3_#21 - VJ_17.05.17_Kinase_screeneing_48h_n3_FFA_005 | 48 | treatment:CHX | concentration:20 µg/ml |
SA163886 | VJ_17.05.13_2_#21 - VJ_17.05.13_Kinase_screeneing_48h_n1_FFA_005 | 48 | treatment:CHX | concentration:20 µg/ml |
SA163887 | VJ_17.05.17_#21 - VJ_17.05.17_Kinase_screeneing_48h_n2_FFA_005 | 48 | treatment:CHX | concentration:20 µg/ml |
SA163888 | VJ_17.05.17_#22 - VJ_17.05.17_Kinase_screeneing_48h_n2_FFA_006 | 48 | treatment:ETO | concentration:10 µM |
SA163889 | VJ_17.05.13_2_#22 - VJ_17.05.13_Kinase_screeneing_48h_n1_FFA_006 | 48 | treatment:ETO | concentration:10 µM |
SA163890 | VJ_17.05.17-n3_#22 - VJ_17.05.17_Kinase_screeneing_48h_n3_FFA_006 | 48 | treatment:ETO | concentration:10 µM |
SA163891 | VJ_17.05.13_2_#27 - VJ_17.05.13_Kinase_screeneing_48h_n1_FFA_011 | 48 | treatment:I3M | concentration:10 µM |
SA163892 | VJ_17.05.17_#27 - VJ_17.05.17_Kinase_screeneing_48h_n2_FFA_011 | 48 | treatment:I3M | concentration:10 µM |
SA163893 | VJ_17.05.17-n3_#27 - VJ_17.05.17_Kinase_screeneing_48h_n3_FFA_011 | 48 | treatment:I3M | concentration:10 µM |
SA163894 | VJ_17.05.17_#26 - VJ_17.05.17_Kinase_screeneing_48h_n2_FFA_010 | 48 | treatment:MC | concentration:10 µM |
SA163895 | VJ_17.05.13_2_#26 - VJ_17.05.13_Kinase_screeneing_48h_n1_FFA_010 | 48 | treatment:MC | concentration:10 µM |
SA163896 | VJ_17.05.17-n3_#26 - VJ_17.05.17_Kinase_screeneing_48h_n3_FFA_010 | 48 | treatment:MC | concentration:10 µM |
SA163900 | VJ_17.05.17_#25 - VJ_17.05.17_Kinase_screeneing_48h_n2_FFA_009 | 48 | treatment:Serum | concentration:- |
SA163901 | VJ_17.05.17-n3_#25 - VJ_17.05.17_Kinase_screeneing_48h_n3_FFA_009 | 48 | treatment:Serum | concentration:- |
SA163902 | VJ_17.05.13_2_#25 - VJ_17.05.13_Kinase_screeneing_48h_n1_FFA_009 | 48 | treatment:Serum | concentration:- |
SA163897 | VJ_17.05.17-n3_#20 - VJ_17.05.17_Kinase_screeneing_48h_n3_FFA_004 | 48 | treatment:STS | concentration:0.3 µM |
SA163898 | VJ_17.05.13_2_#20 - VJ_17.05.13_Kinase_screeneing_48h_n1_FFA_004 | 48 | treatment:STS | concentration:0.3 µM |
SA163899 | VJ_17.05.17_#20 - VJ_17.05.17_Kinase_screeneing_48h_n2_FFA_004 | 48 | treatment:STS | concentration:0.3 µM |
SA163903 | VJ_17.05.13_2_#19 - VJ_17.05.13_Kinase_screeneing_48h_n1_FFA_003 | 48 | treatment:TNFα | concentration:10 ng/ml |
SA163904 | VJ_17.05.17-n3_#19 - VJ_17.05.17_Kinase_screeneing_48h_n3_FFA_003 | 48 | treatment:TNFα | concentration:10 ng/ml |
SA163905 | VJ_17.05.17_#19 - VJ_17.05.17_Kinase_screeneing_48h_n2_FFA_003 | 48 | treatment:TNFα | concentration:10 ng/ml |
SA163906 | VJ_17.05.17-n3_#23 - VJ_17.05.17_Kinase_screeneing_48h_n3_FFA_007 | 48 | treatment:TPG | concentration:2 µM |
SA163907 | VJ_17.05.17_#23 - VJ_17.05.17_Kinase_screeneing_48h_n2_FFA_007 | 48 | treatment:TPG | concentration:2 µM |
SA163908 | VJ_17.05.13_2_#23 - VJ_17.05.13_Kinase_screeneing_48h_n1_FFA_007 | 48 | treatment:TPG | concentration:2 µM |
SA163909 | VJ_17.05.13_2_#24 - VJ_17.05.13_Kinase_screeneing_48h_n1_FFA_008 | 48 | treatment:VAL | concentration:10 µM |
SA163910 | VJ_17.05.17-n3_#24 - VJ_17.05.17_Kinase_screeneing_48h_n3_FFA_008 | 48 | treatment:VAL | concentration:10 µM |
SA163911 | VJ_17.05.17_#24 - VJ_17.05.17_Kinase_screeneing_48h_n2_FFA_008 | 48 | treatment:VAL | concentration:10 µM |
SA163912 | VJ_17.05.17-n3_#28 - VJ_17.05.17_Kinase_screeneing_48h_n3_FFA_012 | 48 | treatment:vehicle (DMSO) | concentration:- |
SA163913 | VJ_17.05.17_#28 - VJ_17.05.17_Kinase_screeneing_48h_n2_FFA_012 | 48 | treatment:vehicle (DMSO) | concentration:- |
SA163914 | VJ_17.05.13_2_#28 - VJ_17.05.13_Kinase_screeneing_48h_n1_FFA_012 | 48 | treatment:vehicle (DMSO) | concentration:- |
SA163915 | VJ_17.05.17-n3_#18 - VJ_17.05.17_Kinase_screeneing_48h_n3_FFA_002 | 48 | treatment:vehicle (DMSO) | concentration:- |
SA163916 | VJ_17.05.17_#18 - VJ_17.05.17_Kinase_screeneing_48h_n2_FFA_002 | 48 | treatment:vehicle (DMSO) | concentration:- |
SA163917 | VJ_17.05.13_2_#18 - VJ_17.05.13_Kinase_screeneing_48h_n1_FFA_002 | 48 | treatment:vehicle (DMSO) | concentration:- |
Showing results 1 to 33 of 33 |